MicroRNA‑466 inhibits the aggressive behaviors of hepatocellular carcinoma by directly targeting metadherin Retraction in /10.3892/or.2022.8357

Jia,Chen; Tang,Desheng; Sun,Chen; Yao,Lei; Li,Fujun; Hu,Yanhua; Zhang,Xinchen; Wu,Dequan

doi:10.3892/or.2018.6763

MicroRNA‑466 inhibits the aggressive behaviors of hepatocellular carcinoma by directly targeting metadherin

Retraction in: /10.3892/or.2022.8357

Authors:
- Chen Jia
- Desheng Tang
- Chen Sun
- Lei Yao
- Fujun Li
- Yanhua Hu
- Xinchen Zhang
- Dequan Wu
View Affiliations

Affiliations: Department of Liver Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150086, P.R. China
Published online on: October 3, 2018 https://doi.org/10.3892/or.2018.6763
Pages: 3890-3898

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous microRNAs (miRNAs) have been demonstrated to be downregulated or upregulated in hepatocellular carcinoma (HCC) and play important roles in its occurrence and development. Therefore, the investigation of miRNAs and their functions implicated in the genesis and development of HCC may provide key clues for the identification of effective therapeutic approaches for patients with this disease. The aims of the present study were to detect miRNA‑466 (miR‑466) expression in HCC tissues and cell lines and to determine its effects on HCC cell proliferation, apoptosis and metastasis, as well as to explore the mechanisms underlying the tumor‑suppressing roles of miR‑466 in HCC. In the present study, reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) was performed to detect miR‑466 expression in HCC tissues and cell lines. The effects of miR‑466 upregulation on HCC cell proliferation, apoptosis, migration and invasion were determined using Cell Counting Kit‑8 assay, flow cytometry analysis and Transwell chamber assay, respectively. The potential target gene of miR‑466 was predicted using bioinformatic analysis, which was further confirmed by luciferase reporter assay, RT‑qPCR and western blot analysis. It was found that miR‑466 was obviously decreased in HCC tissues and cell lines. The results of functional experiments revealed that restoration of miR‑466 expression suppressed the proliferation, induced apoptosis, and reduced the metastasis of HCC cells. In addition, metadherin (MTDH) was identified as a direct target of miR‑466 in HCC cells. Furthermore, MTDH was upregulated in HCC tissues, which was inversely correlated with the miR‑466 level. Moreover, inhibition of MTDH displayed similar tumor‑suppressing roles as miR‑466 upregulation in HCC cells. In addition, MTDH reintroduction restored the tumor‑suppressor activity of miR‑466 overexpression in HCC cells. These findings suggest that miR‑466 is a potential therapeutic tool for HCC therapy.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Global Burden of Disease Cancer Collaboration, . Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 3:524–548. 2017. View Article : Google Scholar : PubMed/NCBI
4	Galun D, Basaric D, Zuvela M, Bulajic P, Bogdanovic A, Bidzic N and Milicevic M: Hepatocellular carcinoma: From clinical practice to evidence-based treatment protocols. World J Hepatol. 7:2274–2291. 2015. View Article : Google Scholar : PubMed/NCBI
5	Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Gardini A, Cescon M, Varotti G, Cetta F and Cavallari A: Liver resection for hepatocellular carcinoma on cirrhosis: Univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 237:536–543. 2003. View Article : Google Scholar : PubMed/NCBI
6	Nguyen VT, Law MG and Dore GJ: Hepatitis B-related hepatocellular carcinoma: Epidemiological characteristics and disease burden. J Viral Hepat. 16:453–463. 2009. View Article : Google Scholar : PubMed/NCBI
7	Yates LA, Norbury CJ and Gilbert RJ: The long and short of microRNA. Cell. 153:516–519. 2013. View Article : Google Scholar : PubMed/NCBI
8	Hammond SM: An overview of microRNAs. Adv Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
9	Xie B, Ding Q, Han H and Wu D: miRCancer: A microRNA-cancer association database constructed by text mining on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
10	Bishop KS, Xu H and Marlow G: Epigenetic regulation of gene expression induced by butyrate in colorectal cancer: Involvement of MicroRNA. Genet Epigenet. 9:1179237X177299002017. View Article : Google Scholar : PubMed/NCBI
11	Wang X, Ivan M and Hawkins SM: The role of MicroRNA molecules and MicroRNA-regulating machinery in the pathogenesis and progression of epithelial ovarian cancer. Gynecol Oncol. 147:481–487. 2017. View Article : Google Scholar : PubMed/NCBI
12	Zhou K, Liu M and Cao Y: New Insight into microRNA functions in cancer: Oncogene-microRNA-tumor suppressor gene network. Front Mol Biosci. 4:462017. View Article : Google Scholar : PubMed/NCBI
13	Yi PS and Li JS: High expression of miR-21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma. Mol Clin Oncol. 8:733–739. 2018.PubMed/NCBI
14	Ding W, Tan H, Li X, Zhang Y, Fang F, Tian Y, Li J and Pan X: MicroRNA-493 suppresses cell proliferation and invasion by targeting ZFX in human hepatocellular carcinoma. Cancer Biomark. 22:427–434. 2018. View Article : Google Scholar : PubMed/NCBI
15	Han G, Zhang L, Ni X, Chen Z, Pan X, Zhu Q, Li S, Wu J, Huang X and Wang X: MicroRNA-873 promotes cell proliferation, migration, and invasion by directly targeting TSLC1 in hepatocellular carcinoma. Cell Physiol Biochem. 46:2261–2270. 2018. View Article : Google Scholar : PubMed/NCBI
16	Chen Z, Zuo X, Zhang Y, Han G, Zhang L, Wu J and Wang X: miR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect. Cell Death Dis. 9:5492018. View Article : Google Scholar : PubMed/NCBI
17	Yu Z, Lin X, Tian M and Chang W: microRNA196b promotes cell migration and invasion by targeting FOXP2 in hepatocellular carcinoma. Oncol Rep. 39:731–738. 2018.PubMed/NCBI
18	Sun X, Wang M, Liu H and Wang J: MicroRNA-423 enhances the invasiveness of hepatocellular carcinoma via regulation of BRMS1. Am J Transl Res. 9:5576–5584. 2017.PubMed/NCBI
19	Zhu W, Qian J, Ma L, Ma P, Yang F and Shu Y: miR-346 suppresses cell proliferation through SMYD3 dependent approach in hepatocellular carcinoma. Oncotarget. 8:65218–65229. 2017.PubMed/NCBI
20	Jiang D, Cho W, Li Z, Xu X, Qu Y, Jiang Z, Guo L and Xu G: miR-758-3p suppresses proliferation, migration and invasion of hepatocellular carcinoma cells via targeting MDM2 and mTOR. Biomed Pharmacother. 96:535–544. 2017. View Article : Google Scholar : PubMed/NCBI
21	Tong F, Ying Y, Pan H, Zhao W, Li H and Zhan X: MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC). Bosn J Basic Med Sci. 18:252–259. 2018.PubMed/NCBI
22	Colden M, Dar AA, Saini S, Dahiya PV, Shahryari V, Yamamura S, Tanaka Y, Stein G, Dahiya R and Majid S: MicroRNA-466 inhibits tumor growth and bone metastasis in prostate cancer by direct regulation of osteogenic transcription factor RUNX2. Cell Death Dis. 8:e25722017. View Article : Google Scholar : PubMed/NCBI
23	Zhou LL, Shen Y, Gong JM, Sun P and Sheng JH: MicroRNA-466 with tumor markers for cervical cancer screening. Oncotarget. 8:70821–70827. 2017.PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Zheng J, Li C, Wu X, Yang Y, Hao M, Sheng S, Sun Y, Zhang H, Long J and Hu C: Astrocyte elevated gene-1 is a novel biomarker of epithelial-mesenchymal transition and progression of hepatocellular carcinoma in two China regions. Tumour Biol. 35:2265–2269. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, Ding ZB, Shi GM, Ke AW, Yang XR, et al: Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 17:7294–7302. 2011. View Article : Google Scholar : PubMed/NCBI
27	Gong Z, Liu W, You N, Wang T, Wang X, Lu P, Zhao G, Yang P, Wang D and Dou K: Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma. Oncol Rep. 27:2073–2079. 2012.PubMed/NCBI
28	Ahn S, Hyeon J and Park CK: Metadherin is a prognostic predictor of hepatocellular carcinoma after curative hepatectomy. Gut Liver. 7:206–212. 2013. View Article : Google Scholar : PubMed/NCBI
29	Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, Mukhopadhyay ND, Mills AS, Waxman S, Fisher RA, Llovet JM, et al: Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest. 119:465–477. 2009. View Article : Google Scholar : PubMed/NCBI
30	Srivastava J, Siddiq A, Emdad L, Santhekadur PK, Chen D, Gredler R, Shen XN, Robertson CL, Dumur CI, Hylemon PB, et al: Astrocyte elevated gene-1 promotes hepatocarcinogenesis: Novel insights from a mouse model. Hepatology. 56:1782–1791. 2012. View Article : Google Scholar : PubMed/NCBI
31	Sarkar D: AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res. 120:193–221. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zhu HD, Liao JZ, He XX and Li PY: The emerging role of astrocyte-elevated gene-1 in hepatocellular carcinoma (Review). Oncol Rep. 34:539–546. 2015. View Article : Google Scholar : PubMed/NCBI
33	Mao B and Wang G: MicroRNAs involved with hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820. 2015. View Article : Google Scholar : PubMed/NCBI
34	Yao M, Wang L, Yao Y, Gu HB and Yao DF: Biomarker-based MicroRNA therapeutic strategies for hepatocellular carcinoma. J Clin Transl Hepatol. 2:253–258. 2014.PubMed/NCBI
35	Lyra-González I, Flores-Fong LE, González-Garcia I, Medina-Preciado D and Armendáriz-Borunda J: MicroRNAs dysregulation in hepatocellular carcinoma: Insights in genomic medicine. World J Hepatol. 7:1530–1540. 2015. View Article : Google Scholar : PubMed/NCBI
36	Shi SQ, Ke JJ, Xu QS, Wu WQ and Wan YY: Integrated network analysis to identify the key genes, transcription factors, and microRNAs involved in hepatocellular carcinoma. Neoplasma. 65:66–74. 2018. View Article : Google Scholar : PubMed/NCBI
37	Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, Volsky DJ and Fisher PB: Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 21:3592–3602. 2002. View Article : Google Scholar : PubMed/NCBI
38	Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, Wu J, Yuan J, Zhang HZ, Zeng MS and Li M: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res. 14:3319–3326. 2008. View Article : Google Scholar : PubMed/NCBI
39	Gnosa S, Shen YM, Wang CJ, Zhang H, Stratmann J, Arbman G and Sun XF: Expression of AEG-1 mRNA and protein in colorectal cancer patients and colon cancer cell lines. J Transl Med. 10:1092012. View Article : Google Scholar : PubMed/NCBI
40	Li WF, Wang G, Zhao ZB and Liu CA: High expression of metadherin correlates with malignant pathological features and poor prognostic significance in papillary thyroid carcinoma. Clin Endocrinol (Oxf). 83:572–580. 2015. View Article : Google Scholar : PubMed/NCBI
41	Yang G, Zhang L, Lin S, Li L, Liu M, Chen H, Cao M, Liu D, Huang YR and Bo J: AEG-1 is associated with tumor progression in nonmuscle-invasive bladder cancer. Med Oncol. 31:9862014. View Article : Google Scholar : PubMed/NCBI
42	Shi X and Wang X: The role of MTDH/AEG-1 in the progression of cancer. Int J Clin Exp Med. 8:4795–4807. 2015.PubMed/NCBI
43	Hu G, Wei Y and Kang Y: The multifaceted role of MTDH/AEG-1 in cancer progression. Clin Cancer Res. 15:5615–5620. 2009. View Article : Google Scholar : PubMed/NCBI
44	Zhao Y, Moran MS, Yang Q, Liu Q, Yuan C, Hong S and Kong B: Metadherin regulates radioresistance in cervical cancer cells. Oncol Rep. 27:1520–1526. 2012.PubMed/NCBI